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Although hypereosinophilia (HE) associated with chronic graft-versus-host disease (GVHD) has long been
recognized, biological data on this phenomenon are scarce. Here we compare patients with chronic GVHD
with HE together with a clonal T cell expansion and control patients with acute or chronic GVHD but without
HE. These clonal expansions share a CD8þ TC1 phenotype rather than a CD4þ Th2 proﬁle. In contrast to the
drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, these allogeneic CD8þ clones do
not recognize the epitopes of herpesviruses. Furthermore, these TC1 clones do not produce IL-17 as described
in the DRESS syndrome.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Chronic graft-versus-host disease (GVHD), the leading
cause of nonrelapse mortality after allogeneic stem cell trans-
plantation, is frequently associated with hypereosinophilia
(HE). HE may precede or be present at the diagnosis of GVHD,
or may reappear with ﬂare-ups [1]. HE was speciﬁcally
mentioned in the ﬁrst published description of chronic GVHD
[2] and has been added to the nondiagnostic criteria by the
National InstitutesofHealthConsensusConferenceonChronic
GVHD [3]. Despite this, however, the biology of HE associated
with chronic GVHD has been poorly described to date [4,5]. In
this report, we describe HE occurring together with a clonal
T cell expansion of the TC1 phenotype.PATIENTS AND METHODS
Patients
We studied 6 adult patients (5 males and 1 female) with extensive
chronic GVHD-associated HE and 4 adult controls with acute or chronic
GVHD but without HE. Five patients with HE and 2 controls had undergone
transplantation with peripheral blood stem cells. The donor was an HLA-
identical sibling for 4 of the 5 patients and for both controls. All but 1 pa-
tient with HE underwent transplantation for a hematologicmalignancy after
a reduced-intensity conditioning regimen. At the onset of HE, all patients
were in hematologic remission, with 100% donor chimerism based on
quantitative PCR (qPCR) of variable number tandem repeat sequences.
GVHD characteristics are summarized in Table 1. This study was approved by
the Ethics Committee of Saint-Louis Hospital.Methods
T cell repertoire
Peripheral blood mononuclear cells were separated using a lymphocyte
separationmedium (Eurobio, Les Ulis, France), and 5-10106 cellswere stored
after lysis in TriReagent solution (Molecular Research Center, Cincinnati, OH)
at 80C. RNA was subsequently extracted following the manufacturer’s
instructions. Then 2-5 mg of total RNAwas reverse-transcribed into cDNAusing
the Superscript III ﬁrst-strand synthesis system for RT-PCR (Invitrogen,
Cergy-Pontoise, France). T cell receptor beta V qPCR ampliﬁcation, beta chain
variable and constant runoff using an internal beta chain constant ﬂuores-
cent primer, gel running, and immunoscope analysis were performed as
described previously [6].
Table 1
GVHD Characteristics
Patient GVHD Time from Transplantation to GVHD, d Time from GVHD to Sampling, d GVHD at Sampling Treatment at Sampling
Ctrl1 Chronic 257 84 PR CSA
Ctrl2 Acute 134 52 CR Steroids (0.15 mg/kg)
Ctrl3 Acute 43 160 PR Steroids (0.15 mg/kg)
Ctrl4 Chronic 174 189 CR Steroids
HE1 Chronic 359 571 CR Steroids (0.2 mg/kg) þ CSA þ MMF
HE2 Chronic 423 1705 PR CSA þ local
HE3 Chronic 140 1407 CR Local
HE4 Chronic 195 126 Flare CSA
HE5 Chronic 570 1068 Flare Steroids (0.25 mg/kg) þ MMF
HE6 Chronic 118 0 Flare CSA
Ctrl indicates control; CSA, cyclosporin A; MMF, mycophenolate mofetil; CR, complete response; PR, partial response.
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Cells were thawed and left to rest overnight at 37C in RPMI 10% medium
with 10% humanAB serum. Theywere then stimulated in 96-well plates using
50 ng/mL PMA (Phorbol 12-Myristate 13-Acetate), 1 mM ionomycin, and 1 mg/
mL brefeldin A (all from Sigma-Aldrich, Lyon, France). After 4 hours, cells were
harvested, permeabilized using the Human FoxP3 Buffer Set (BD Pharmingen,
Le Pont de Claix, France), and stained with the following antibodies: CD3
Amcyan, CD8 PerCP, PD1 (CD279) PE, CTLA4 (CD152) APC, IL5 PE, TNFa PE-Cy7,
perforin FITC (all from BD Pharmingen), TCRVb3 FITC (Beckman-Coulter,
Villepinte, France), and IL17 PE (eBioscience, Paris, France). Appropriate
isotype-matched controls (BD Biosciences) were included. At least 10,000
lymphocytes were acquired with a FACSCanto II cytometer (BD Biosciences).
Mass sequencing
In 4 of the patients with HE (including donor, M4, M5, M6, and M24 for
patient HE6) and all control patients, Vb3 and Vb6 were ampliﬁed from
qPCR product with a primer containing the sequencing primer TitA, a
2-nucleotide patient-speciﬁc tag, the constant region primer HTCB3
(TitA_tag_HTCB3) (CCATCTCATCCCTGCGTGTCTCCGACTCAG-NN-CCTTTT
GGGTGTGGGAGATCTC), and a Vb3- or Vb6-speciﬁc primer also containing
the TitB sequencing primer (GCGCTCCTTCTTCTCTCTAGAGAC-CTGAGACT
GCCAAGGCACACAGGGGATAGG, or GAAATTGGATCACACCTGAG-CTGAGA
CTGCCAAGGCACACAGGGGATAGG, respectively).
All PCR products were pooled and sequenced together in a single run on
a GS FLXþ System with a Titanium XLþ Sequencing Kit (Roche, Boulogne-
Billancourt, France) by GATC Biotech, Mulhouse, France. After screening on
the expected size and sorting according to patient tag, sequences were
analyzed and aligned using Galaxy [7]. Analysis of the junctions and
translation of CDR3 were done using IMGT V-Quest [8].
RESULTS AND DISCUSSION
This study was initiated after we encountered a patient
with peripheral T cell lymphoma who developed chronic
GVHD and simultaneous HE. Because HE was present at the
time of diagnosis of lymphoma, a relapse of the lymphoma
was suspected, but this was ruled out by a different TCR
rearrangement on Southern blot analysis. Five additional
patients with HE were then analyzed for TCR d locus
recombination by Southern blot analysis, which revealed
clonal T cell expansion (data not shown).
We studied these T cell expansions through quantitative
determination of Vb usage using real time PCR and CDR3 size
polymorphism (spectratyping or immunoscope analysis).
Ten patients were studied, 6 of whom exhibited a clonal
expansion proﬁle. Comparisons of these 6 patients with HE
and 4 controls showed massive expansions in the HE group
(with >40% of families in 2 patients), especially within the
Vb3 and Vb6 families (Figure 1A and Supplemental
Figure S1). Moreover, for patients HE6 and HE4, we were
able to test cells before and after onset of HE. Expansion was
present (66% of all Vb at 6 months post-transplantation) and
persisted long after resolution of HE (44% at 1 year post-
transplantation). Follow-up of patient HE6 is shown in
Figure 1B and C.We then conﬁrmed Tcell clonality usingmass sequencing,
with >90% of the sequences corresponding to 1 clonotype.
The same clonotypewas found at 4, 5, 6, and 24months post-
transplantation, but was not detected in either the donor
(85 independent sequences) or the 3 other patients with HE
and the 4 controls (Supplemental Figure S1). A search for
sequence homology with the other published CDR3 se-
quences was negative (Figure 1D).
In 2 patients, we then characterized the clonal expan-
sions using a Vb3-speciﬁc antibody, given that Vb6 antibody
is not commercially available (Figure 2). Vb3 staining
conﬁrmed our qPCR data, and, unexpectedly, the expansion
was restricted to the CD8þ T cells. On unspeciﬁc stimulation
(with PMA-ionomycin), these Vb3 CD8þ T cells did not ex-
press IL-5 or IL-17A, but did express TC1 cytokines, IFN-g,
and TNF-a. Furthermore, all CD8þ T cells were positive for
perforin but negative for PD1 and surface CTLA4 (data not
shown).
Activated CD8þ T lymphocytes have recently been impli-
cated in mediating the drug reaction with eosinophilia and
systemic symptoms (DRESS) syndrome [9]. In DRESS, these
CD8þ T cells are largely directed against herpesviruses,
particularly Epstein-Barr virus (EBV). Thus, we evaluated the
link between cytomegalovirus (CMV) or EBV and chronic
GVHDeassociated HE within the aforementioned Vb3 clone.
In patient HE6, we detected a low EBV and high CMV CD8þ
response (especially against the CMV antigen IE1), whichwas
nevertheless independent of the Vb3 clone (Supplemental
Figure S2).
To summarize, we detected clonal T cell expansion in
some patients with chronic GVHDeassociated HE. Although
we would have expected to ﬁnd an IL-5edriven Th2 phe-
nomenon [10], we did ﬁnd that the T cell expansions were
CD8þ with a TC1 (IFN-g and TNF-a) phenotype, occurring
mainly within the Vb3 and Vb6 families. As noted previously,
CD8þ T cells with a TC1 phenotype have been described in
DRESS syndrome as well [9]; however, unlike in DRESS
syndrome, we found no evidence for a phenomena driven by
herpesviruses, and a mechanical gap clearly persists be-
tween these clonal T cell expansions and the occurrence of
HE (as is the case for DRESS). Although we cannot rule out
the possibility that these clonal T cell expansions simply
reﬂect allogeneic recognition [11] with no direct link to HE,
we must note that alloreactivity was present in the patients
with chronic GVHD without HE (Figure 1A). Another possi-
bility is that HE in patients with chronic GVHD is driven
by cytokines other than IL-5; however, the cytokines impli-
cated in HE (i.e. IL-3, GM-CSF, and IL-33) are not T celle
derived [10].
Figure 2. Phenotypic characterization and cytokine production of Vb3 T cell expansion in patient HE6. (A) Surface Vb3 staining of CD3þ cells at 4, 6, and 24 mo post-
transplantation. Shown are percentages of cells as a proportion of total CD3þ cells (as gated in the left panel). (B) Intracellular cytokine staining of the CD3þCD8þ cells
of patient HE6 at 24 mo post-transplantation. Cells were stimulated for 4 h with PMA-ionomycin before staining. Percentages in the top right of each plot refer to
cytokine-positive cells as a proportion of total CD8þ Vb3þ cells.
Figure 1. Massive Vb expansion occurs in patients with chronic GVHD with HE. (A) Vb family usage measured by qRT-PCR in 10 patients with chronic GVHD, 6 with
HE (in blue) and 4 without (in green). (B) Vb family usage for patient HE6 at months 4, 5 (as in A), 6, and 24 post-transplantation and for the corresponding donor (D).
(C) Characterization of Vb3 expansion in patient HE6. Percentage of use was obtained by qPCR, and CDR3 size polymorphism (immunoscope analysis or spec-
tratyping) and Vb3 sequences were obtained by mass sequencing. The last value indicates the percentage of independent sequences corresponding to the main
clonotype (see Methods). (D) CDR3 nucleotide sequence and translation of the main Vb3 clonotype for patient HE6.
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Hematological malignancies often express surface HLA class II, making them attractive targets for CD4þ T cell
therapy. We previously demonstrated that HLA class II ligands can be divided into DM-resistant and DM-
sensitive antigens. In contrast to presentation of DM-resistant antigens, presentation of DM-sensitive anti-
gens is suppressed by HLA-DM but can be rescued by HLA-DO. We also showed that HLA-DO expression
remains low in nonhematopoietic cells under inﬂammatory conditions, suggesting that DM-sensitive anti-
gens may be ideal T cell targets with a low risk for graft-versus-host disease. Here, we demonstrated that
B cell malignancies often express HLA-DO and that levels are in particular high in chronic lymphocytic
leukemia. Moreover, we showed that surface presentation of DM-sensitive antigens is regulated by HLA-DO,
and that DM-sensitive antigens are relevant T cell targets for B cell malignancies and, especially, chronic
lymphocytic leukemia. These data open the perspective to target HLA class II ligands with speciﬁc processing
and presentation behavior for CD4þ T cell therapy of hematological malignancies.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic stemcell transplantation (aSCT) in the treatment
of hematological malignancies is the most successful form of
cellular immunotherapy [1]. The beneﬁcial graft-versus-
leukemia (GVL) effect is mediated by donor-derived T cells
recognizing residual leukemic cells of the patient [2]. These
T cells, however, may also react against nonhematopoietic
tissues of the patient, thereby inducing graft-versus-host
